Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd. and other investors
June 04, 2019
Share
Komipharm International Co., Ltd. (KOSDAQ:A041960) announced a private placement of 13th series unregistered coupon unguaranteed private convertible bonds for gross proceeds of KRW 10,000,000,000 on June 5, 2019. The transaction will include participation from existing investor SUSUNG ASSET MANAGEMENT Co., Ltd. for KRW 1,000,000,000 and funds managed by Soosung Lift Mfg.Co., Ltd. for KRW 9,000,000,000. The bonds carry no coupon rate and will mature on June 10, 2024. The bonds will be fully convertible into 378,299 shares at a fixed conversion price of KRW 26,439 per share between June 10, 2020 and May 10, 2024. The transaction is expected to close on June 10, 2019. The transaction has been approved by the board of directors of the company.
Komipharm International Co Ltd is a Korea-based company principally engaged in the development and manufacture of veterinary vaccines and veterinary pharmaceuticals. The Companyâs main products include veterinary vaccines such as total vaccines of respiratory disease for swine, vaccines of anthrax disease and black leg for cattle, vaccines for infectious bronchitis and Newcastle disease, and canine respiratory infection killed vaccines, and veterinary pharmaceuticals such as antibiotics, nutrients, disinfectants and others, which are used to treat pneumonia, pasteurellosis, enteritis, mastitis, swine erysipelas, septicemia, leptospirosis and bacterial diseases for livestock. The Company also engages in research and development of anticancer drugs and cancer pain-relieving agents. In addition, the Company provides services such as pathological biopsies, serum tests, and bacteria tests.
Komipharm International Co., Ltd. announced that it expects to receive KRW 10 billion in funding from SUSUNG ASSET MANAGEMENT Co., Ltd. and other investors
KOMIPHARM INTERNATIONAL CO., LTD. 
